NEW YORK (GenomeWeb) – OpGen has raised about $1.1 million toward a targeted $1.5 million financing round, the firm disclosed in a regulatory document recently.

A spokesperson for the Gaithersburg, Md.-based microbial genetics analysis firm said that the initial funds are part of a Series B financing round that OpGen expects to close in the fall. It will use the money to commercialize the Acuitas MDRO Gene Test, a molecular test for identifying patients at risk of harboring antibiotic-resistant disease-causing microbes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.